Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C48636
http://purl.obolibrary.org/obo/NCIT_C48636
Preferred Name

Lenvatinib Mesylate
Definitions
A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. E7080 blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. E7080 blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.
label
Lenvatinib Mesylate
prefLabel
Lenvatinib Mesylate
Has_Free_Acid_Or_Base_Form
Legacy Concept Name
E7080
in_subset
Preferred_Name
Lenvatinib Mesylate
Is_Value_For_GDC_Property
Chemical_Formula
C21H19ClN4O4.CH4O3S
Display_Name
Lenvatinib Mesylate
Maps_To
Lenvatinib Mesylate
PDQ_Open_Trial_Search_ID
445461
Has_Target
UMLS_CUI
C4018332
FDA_UNII_Code
3J78384F61
prefixIRI
NCIT:C48636
Accepted_Therapeutic_Use_For
locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer; advanced renal cell carcinoma (RCC); first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
NCI_Drug_Dictionary_ID
445461
Contributing_Source
CTRP
FDA
subClassOf
PubMedID_Primary_Reference
18765537
code
C48636
type
PDQ_Closed_Trial_Search_ID
445461
Semantic_Type
Pharmacologic Substance
CAS_Registry
857890-39-2
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display